Free Trial

Axsome Therapeutics (AXSM) News Today

→ It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad)
Free AXSM Stock Alerts
$71.80
-2.10 (-2.84%)
(As of 04:00 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 10 at 12:35 PM | marketbeat.com
Lighthouse Investment Partners LLC Invests $4.47 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Lighthouse Investment Partners LLC purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 56,202 shares of the com
June 7 at 1:48 AM | americanbankingnews.com
Axsome Therapeutics (NASDAQ:AXSM) Given New $130.00 Price Target at Royal Bank of Canada
June 6, 2024 | americanbankingnews.com
Axsome Therapeutics' (AXSM) "Buy" Rating Reiterated at HC Wainwright
June 6, 2024 | marketbeat.com
Axsome Therapeutics (NASDAQ:AXSM) Rating Reiterated by HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $190.00 price objective on shares of Axsome Therapeutics in a research note on Thursday.
June 5, 2024 | marketbeat.com
Royal Bank of Canada Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $130.00
Royal Bank of Canada upped their price objective on shares of Axsome Therapeutics from $127.00 to $130.00 and gave the company an "outperform" rating in a report on Wednesday.
June 5, 2024 | marketbeat.com
50,000 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Bought by Affinity Asset Advisors LLC
Affinity Asset Advisors LLC purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 50,000 shares of the c
June 5, 2024 | globenewswire.com
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
June 4, 2024 | marketbeat.com
Rhenman & Partners Asset Management AB Buys 39,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Rhenman & Partners Asset Management AB boosted its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 97.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,100 shares of the company's stock afte
June 4, 2024 | globenewswire.com
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
June 4, 2024 | americanbankingnews.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Brokerages
May 31, 2024 | americanbankingnews.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman Sells 5,249 Shares
May 30, 2024 | insidertrades.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Sells $394,777.29 in Stock
May 29, 2024 | marketbeat.com
Insider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Sells 5,249 Shares of Stock
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) Director Mark Coleman sold 5,249 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $75.21, for a total transaction of $394,777.29. Following the completion of the sale, the director now owns 19,848 shares in the company, valued at $1,492,768.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
May 29, 2024 | globenewswire.com
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
May 28, 2024 | finance.yahoo.com
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
May 25, 2024 | marketbeat.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Victory Capital Management Inc.
Victory Capital Management Inc. lessened its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 72.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,208 shares of the company's stock after selling 13,726
May 22, 2024 | marketbeat.com
Stock Traders Buy High Volume of Call Options on Axsome Therapeutics (NASDAQ:AXSM)
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors bought 5,695 call options on the company. This is an increase of 483% compared to the typical volume of 977 call options.
May 20, 2024 | markets.businessinsider.com
Hold Rating on Axsome Therapeutics Amidst Regulatory Strategy and Commercialization Prospects
May 20, 2024 | marketbeat.com
National Bank of Canada FI Has $46,000 Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
National Bank of Canada FI cut its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 99.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 600 shares of the company's stock after
May 19, 2024 | marketbeat.com
Swiss National Bank Has $4.82 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Swiss National Bank decreased its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 15.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,500 shares of the company's stock after selling 11,
May 18, 2024 | fool.com
3 Monster Stocks in the Making You Can Buy Right Now
May 17, 2024 | finance.yahoo.com
Axsome Therapeutics, Inc. (AXSM)
May 15, 2024 | marketbeat.com
Nicholas Investment Partners LP Sells 312,335 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Nicholas Investment Partners LP lessened its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 79.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 82,645 shares of the company's stock after s
May 13, 2024 | finance.yahoo.com
15 Most Depressed States in the US
May 11, 2024 | investorplace.com
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
May 11, 2024 | fool.com
Prediction: These 2 Growth Stocks Could Triple By 2030
May 11, 2024 | marketbeat.com
21,086 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Acquired by Truist Financial Corp
Truist Financial Corp purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 21,086 shares of the company's stock, valued at approximate
May 10, 2024 | marketbeat.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) to Post Q2 2024 Earnings of ($1.31) Per Share, HC Wainwright Forecasts
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at HC Wainwright lowered their Q2 2024 earnings estimates for Axsome Therapeutics in a research note issued on Tuesday, May 7th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per sha
May 10, 2024 | seekingalpha.com
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 9, 2024 | finance.yahoo.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 9, 2024 | marketbeat.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) to Post Q3 2025 Earnings of $0.47 Per Share, HC Wainwright Forecasts
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Analysts at HC Wainwright dropped their Q3 2025 EPS estimates for shares of Axsome Therapeutics in a report released on Tuesday, May 7th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.47 f
May 8, 2024 | marketbeat.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $106.00 at Mizuho
Mizuho lowered their price target on shares of Axsome Therapeutics from $109.00 to $106.00 and set a "buy" rating on the stock in a report on Wednesday.
May 8, 2024 | markets.businessinsider.com
Buy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical Trials
May 8, 2024 | marketbeat.com
FY2026 EPS Estimates for Axsome Therapeutics, Inc. Reduced by Analyst (NASDAQ:AXSM)
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at Leerink Partnrs reduced their FY2026 earnings per share (EPS) estimates for Axsome Therapeutics in a report released on Monday, May 6th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn $1.
May 8, 2024 | globenewswire.com
Axsome Therapeutics to Present at Upcoming Investor Conferences
May 7, 2024 | marketbeat.com
Axsome Therapeutics (NASDAQ:AXSM) PT Lowered to $125.00
Citigroup cut their target price on Axsome Therapeutics from $127.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday.
May 7, 2024 | markets.businessinsider.com
Buy Rating Affirmed on Axsome Therapeutics Amid Strong Sales and Strategic Positioning
May 7, 2024 | finance.yahoo.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript
May 7, 2024 | marketbeat.com
Robert W. Baird Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $112.00
Robert W. Baird boosted their price target on Axsome Therapeutics from $108.00 to $112.00 and gave the stock an "outperform" rating in a research report on Tuesday.
May 7, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Axsome Therapeutics on Strong Auvelity Sales and Market Expansion Potential
May 7, 2024 | finance.yahoo.com
Axsome Therapeutics Inc (AXSM) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues ...
May 7, 2024 | finance.yahoo.com
Q1 2024 Axsome Therapeutics Inc Earnings Call
May 6, 2024 | fool.com
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
May 6, 2024 | investorplace.com
AXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 6, 2024 | washingtonpost.com
Axsome: Q1 Earnings Snapshot
May 6, 2024 | msn.com
Axsome Therapeutics GAAP EPS of -$1.44 misses by $0.21, revenue of $75M beats by $2.15M
May 6, 2024 | globenewswire.com
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 2, 2024 | stocknews.com
Investors Beware of These 3 Pharma Stocks
May 2, 2024 | marketbeat.com
Cannell & Co. Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Cannell & Co. lowered its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 20.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 82,845 shares of the company's stock after selling 21,345 shares during the period. Cannell
May 1, 2024 | globenewswire.com
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
Get Axsome Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

It's time to ween off Chinese lithium! (Ad)

As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely

Learn how this American company is leading the lithium-ion revolution

AXSM Media Mentions By Week

AXSM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AXSM
News Sentiment
▼
0.77

0.76
▲
Average
Medical
News Sentiment

AXSM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AXSM Articles
This Week
▼
12

6
▲
AXSM Articles
Average Week

Get Axsome Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:AXSM) was last updated on 6/10/2024 by MarketBeat.com Staff

From Our Partners
It's time to ween off Chinese lithium!
As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...
Smallcaps Daily | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Hurry! Buy this stock before the Robinhood traders do!
Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...
Traders Agency | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
Moonshot Coins for the Current Crypto Run
Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...
Crypto 101 Media | Sponsored
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored